Human PCSK9 Monoclonal Antibody

Catalog No.: YR0154



Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay

Sterility

0.2 µm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical P K and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Evolocumab Biosimilar

Isotype

Human IgG2 lambda

Immunogen

Human PCSK9

RecommendedIsotype Control(s)

Recommended Dilution Buffer

1×PBS pH 7.4

Contact

6	400-999-6126
\bowtie	cn.market@abclonal.com.cr
•	www.abclonal.com.cr

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)